JMP Securities analyst Reni Benjamin lowered the firm’s price target on Sutro Biopharma to $17 from $20 and keeps an Outperform rating on the shares. Sutro recently reported Q4 financial results and provided an update on the key assets in the pipeline, and with STRO-002 initiating a registrational study in 2Q23, STRO-003, a ROR1-targeting ADC to enter the clinic in 2024, multiple marquee partners progressing candidates through development, and a solid cash position of $302.2M, JMP Securities is a buyer of the stock, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on STRO:
- Sutro Biopharma price target lowered to $16 from $20 at H.C. Wainwright
- Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
- Sutro transferred with Equal Weight from Overweight at Wells Fargo
- Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sutro Biopharma appoints Borgman as Chief Medical Officer